Hemosiderin-Laden Macrophages in Bronchoalveolar Lavage: Predictive Role for Acute Exacerbation of Idiopathic Interstitial Pneumonias.
Journal
Canadian respiratory journal
ISSN: 1916-7245
Titre abrégé: Can Respir J
Pays: Egypt
ID NLM: 9433332
Informations de publication
Date de publication:
2021
2021
Historique:
received:
18
07
2021
revised:
20
11
2021
accepted:
04
12
2021
entrez:
30
12
2021
pubmed:
31
12
2021
medline:
27
1
2022
Statut:
epublish
Résumé
Hemosiderin-laden macrophages (HLMs) have been identified in the bronchoalveolar lavage fluid (BALF) of patients with idiopathic pulmonary fibrosis (IPF). This retrospective study examined the ability of HLMs in BALF to predict the acute exacerbation (AE) of chronic idiopathic interstitial pneumonias (IIPs). Two hundred and twenty-one patients with IIP diagnosed by bronchoscopy were enrolled in the study (IPF, Twenty-four patients had a positive HS (range: 7‒132). The receiver-operating characteristic curve analysis identified the cutoff HS value for predicting the AE of IIPs to be 61.5. Seven cases had a higher HS (≥61.5) and 214 had a lower HS. AE occurred significantly earlier in the higher HS group (4/7 cases) than in the lower HS group (41/214 cases) during a median observation period of 1239 days (log-rank test, A higher HS was a significant predictor of AE in IIPs but did not significantly improve the predictive ability of other parameters.
Sections du résumé
Background
Hemosiderin-laden macrophages (HLMs) have been identified in the bronchoalveolar lavage fluid (BALF) of patients with idiopathic pulmonary fibrosis (IPF). This retrospective study examined the ability of HLMs in BALF to predict the acute exacerbation (AE) of chronic idiopathic interstitial pneumonias (IIPs).
Methods
Two hundred and twenty-one patients with IIP diagnosed by bronchoscopy were enrolled in the study (IPF,
Results
Twenty-four patients had a positive HS (range: 7‒132). The receiver-operating characteristic curve analysis identified the cutoff HS value for predicting the AE of IIPs to be 61.5. Seven cases had a higher HS (≥61.5) and 214 had a lower HS. AE occurred significantly earlier in the higher HS group (4/7 cases) than in the lower HS group (41/214 cases) during a median observation period of 1239 days (log-rank test,
Conclusions
A higher HS was a significant predictor of AE in IIPs but did not significantly improve the predictive ability of other parameters.
Identifiants
pubmed: 34966470
doi: 10.1155/2021/4595019
pmc: PMC8712187
doi:
Substances chimiques
Hemosiderin
9011-92-1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4595019Informations de copyright
Copyright © 2021 Toru Arai et al.
Déclaration de conflit d'intérêts
TK, YS, RS, CS, KT, YF, and SH have no conflicts of interest. YI is an advisor to Boehringer Ingelheim, Shionogi Co. Ltd, and Asahi Kasei. TA has received lecture fee from Boehringer Ingelheim and Shionogi Co. Ltd. for activities not connected with the submitted work.
Références
Adv Exp Med Biol. 2017;967:105-137
pubmed: 29047084
Br Med J. 1975 Apr 26;2(5964):166-8
pubmed: 1125726
Respir Res. 2014 Sep 01;15:109
pubmed: 25176016
AJR Am J Roentgenol. 1997 Jan;168(1):79-83
pubmed: 8976924
BMC Pulm Med. 2017 Apr 12;17(1):60
pubmed: 28403845
Am J Surg Pathol. 2007 Feb;31(2):277-84
pubmed: 17255773
Chest. 2008 Jan;133(1):226-32
pubmed: 18071016
Lancet. 2011 Dec 3;378(9807):1949-61
pubmed: 21719092
Biochim Biophys Acta. 2013 Jul;1832(7):1028-40
pubmed: 23219955
Am J Respir Crit Care Med. 2008 Apr 1;177(7):752-62
pubmed: 18202348
Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48
pubmed: 24032382
Hum Pathol. 2007 Jan;38(1):60-5
pubmed: 16949908
Am J Physiol Lung Cell Mol Physiol. 2006 Apr;290(4):L790-L796
pubmed: 16306138
Am J Respir Crit Care Med. 2004 Jun 1;169(11):1203-8
pubmed: 14754760
PLoS One. 2018 Apr 12;13(4):e0194803
pubmed: 29649237
Eur Respir Rev. 2012 Jun 1;21(124):152-60
pubmed: 22654088
Eur Respir J. 2012 Jul;40(1):93-100
pubmed: 22135282
J Clin Invest. 2012 Aug;122(8):2731-40
pubmed: 22850883
Chest. 1993 Jun;103(6):1808-12
pubmed: 8404104
Am J Respir Crit Care Med. 2016 Aug 1;194(3):265-75
pubmed: 27299520
Chest. 2007 Mar;131(3):657-663
pubmed: 17356077
Eur Respir J. 2009 Jun;33(6):1361-6
pubmed: 19129275
Pulm Pharmacol Ther. 2014 Jun;28(1):35-40
pubmed: 24365112
Am J Respir Crit Care Med. 2007 Oct 1;176(7):636-43
pubmed: 17585107
Am J Physiol Lung Cell Mol Physiol. 2004 Jul;287(1):L134-42
pubmed: 15033636
Am J Respir Crit Care Med. 2008 Aug 15;178(4):372-8
pubmed: 18451320
J Lab Clin Med. 1991 Jun;117(6):493-9
pubmed: 2045717
Eur Respir J. 2004 Jun;23(6):932-46
pubmed: 15219010
Chest. 1984 Sep;86(3):409-11
pubmed: 6468000
Eur Respir J. 2015 Feb;45(2):483-90
pubmed: 25504993
Respirology. 2017 Oct;22(7):1363-1370
pubmed: 28508494
Sarcoidosis Vasc Diffuse Lung Dis. 2010 Jul;27(2):103-10
pubmed: 21319592
Thromb Haemost. 2013 Apr;109(4):696-705
pubmed: 23364276
Am J Respir Crit Care Med. 2012 May 1;185(9):1004-14
pubmed: 22550210
Respirology. 2016 Nov;21(8):1431-1437
pubmed: 27460223
Respirology. 2019 Jul;24(7):658-666
pubmed: 30835911
PLoS One. 2016 Sep 29;11(9):e0163677
pubmed: 27684705
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
PLoS One. 2015 Jan 15;10(1):e0116775
pubmed: 25590613
BMC Pulm Med. 2017 Feb 6;17(1):30
pubmed: 28166761
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
Eur Respir J. 2006 Jan;27(1):108-13
pubmed: 16387942
Pulm Pharmacol Ther. 2015 Jun;32:1-6
pubmed: 25862941
Respir Res. 2010 Apr 14;11:37
pubmed: 20398288